Coated implants
A prosthesis comprising a water-dissolvable coating. A prosthesis for a lacrimal canaliculus comprising a swellable punctal plug with a proximal end and a distal end, with the plug comprising a water-dissolvable biocompatible coating on the distal and/or the proximal end. Materials and methods for making and using the same. A prosthesis for placement in or across natural or prosthetic lumens, ostia, ducts, sinus, or sphincters, the prosthesis comprising a coating. The prosthesis can further provide a depot for sustained drug delivery to tissue.
1. A prosthesis for passage into an opening in a tissue, the prosthesis comprising
a swellable punctal plug with a body having a proximal end and a distal end, wherein the plug, when placed in physiological solution and allowed to freely expand, swells from 10% to 300% in volume,
the prosthesis further comprising a water-dissolvable coating on the swellable punctal plug that forms an ellipsoid shape such that the ellipsoid covers a portion of the body and the distal end and continuously extends from 0.1 mm to 3 mm beyond the distal end to provide a tip for the prosthesis.
2. The prosthesis of claim 1 wherein the coating comprises a water soluble material.
3. The prosthesis of claim 2 wherein the water soluble material consists essentially of a hydrophilic polymer.
4. The prosthesis of claim 2 wherein the water soluble material comprises a hydrophilic polymer that comprises polyethylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, cellulose, polyacrylic acid, polyethyleneimine, peptide, or polysaccharide.
5. The prosthesis of claim 1 wherein the coating encapsulates the punctal plug.
6. The prosthesis of claim 1 wherein the plug and/or coating further comprises a therapeutic agent.
7. The prosthesis of claim 6 wherein the agent is for treatment of an ocular condition.
8. The prosthesis of claim 7 wherein the ocular condition is age-related macular degeneration (AMD) cystoid macular edema (CME), diabetic macular edema (DME), posterior uveitis, diabetic retinopathy, or glaucoma.
9. The prosthesis of claim 8 wherein the agent comprises anti-VEGF, a VEGFR1 inhibitor, a VEGFR2 inhibitor, a VEGFR3 inhibitor, anti-PDGF, anti-PDGF-R, a PDGFRβ inhibitor, an anti-angiogenic agent, sunitinib, E7080, Takeda-6d, tivozanib, regorafenib, sorafenib, pazopanib, axitinib, nintedanib, cediranib, vatalanib, motesanib, a macrolide, sirolimus, everolimus, a tyrosine kinase inhibitor (TKI), imatinib, gefinitib, toceranib, erlotinib, nilotinib, bosutinib neratinib, lapatinib, nepafenac, tacrolimus, moxifloxacin, dexamethasone, travoprost, a steroid, a fluoroquinolone, a prostaglandin analog, a prostamide, or an mTOR receptor inhibitor.
10. The prosthesis of claim 1 wherein the coating further comprises a visualization agent detectable by an unaided human eye.
11. The prosthesis of claim 1 wherein the coating is a solid at a physiological temperature and has a melting point in a range from 40 to 100 degrees Celsius.
12. The prosthesis of claim 1 wherein the coating essentially dissolves in a physiological solution in no more than 15 minutes.
13. The prosthesis of claim 1 wherein the coating does not contact the proximal end.
14. The prosthesis of claim 13 wherein the coating comprises a visualization agent to indicate an orientation of the punctal plug.
15. The prosthesis of claim 1 wherein the tip has a rounded terminus.